GlucoTrack, Inc. (NASDAQ:GCTK) Director Buys $230,000.40 in Stock

GlucoTrack, Inc. (NASDAQ:GCTK) Director Drew Sycoff purchased 182,540 shares of GlucoTrack stock in a transaction on Monday, April 22nd. The shares were acquired at an average cost of $1.26 per share, with a total value of $230,000.40. Following the completion of the transaction, the director now directly owns 2,951,258 shares in the company, valued at approximately $3,718,585.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

GlucoTrack Stock Performance

GCTK opened at $0.46 on Friday. GlucoTrack, Inc. has a 12-month low of $0.13 and a 12-month high of $0.99. The company has a current ratio of 3.22, a quick ratio of 3.22 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $12.23 million, a PE ratio of -1.23 and a beta of 0.29. The firm has a 50 day moving average of $0.39 and a two-hundred day moving average of $0.28.

GlucoTrack (NASDAQ:GCTK) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.10) earnings per share (EPS) for the quarter.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.